RiboMic is a Japanese biopharmaceutical company specializing in the research and development of aptamer-based medicines (a form of nucleic acid drug), positioning aptamers as next-generation therapeutics following antibody drugs. The company leverages its proprietary drug discovery platform, 'RiboART System®', to design and develop innovative aptamer drug candidates targeting unmet medical needs. Its lead asset, umedaptanib pegol (RBM-007), an anti-FGF2 aptamer, is currently in clinical development for achondroplasia (a rare skeletal dysplasia) and wet age-related macular degeneration (wet AMD).
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →RiboMic is a Japanese biopharmaceutical company specializing in the research and development of aptamer-based medicines (a form of nucleic acid drug), positioning aptamers as next-generation therapeutics following antibody drugs. The company leverages its proprietary drug discovery platform, 'RiboART System®', to design and develop innovative aptamer drug candidates targeting unmet medical needs. Its lead asset, umedaptanib pegol (RBM-007), an anti-FGF2 aptamer, is currently in clinical development for achondroplasia (a rare skeletal dysplasia) and wet age-related macular degeneration (wet AMD).
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →